Skip to main content
Erschienen in: Journal of Thrombosis and Thrombolysis 4/2017

14.09.2017

Reversal of dabigatran-associated bleeding using idarucizumab: review of the current evidence

verfasst von: Michela Giustozzi, Melina Verso, Giancarlo Agnelli, Cecilia Becattini

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Major bleeding occurs in about 4% of patients while on treatment with direct oral anticoagulants (DOACs). The case-fatality rate associated with these events is estimated to be about 5%. The specific roles of antidotes, when used with DOACs in reducing the case fatality or improving the overall clinical course of these events, are not thoroughly understood. To this regard, the US Food and Drug Administration as well as European Medicines Agency have recently licensed idarucizumab for the management of patients with life-threatening bleeding or the need for urgent surgery/procedures while on treatment with dabigatran. Specifically, idarucizumab is a humanized monoclonal antibody fragment that rapidly reverses the anticoagulant effect of dabigatran. Two other antidotes, andeXanet and ciraparantag are currently under evaluation for reversal of DOACs. Here, we report on the use of idarucizumab in two patients who experienced life-threatening bleeding while on treatment with dabigatran for atrial fibrillation and provide a review highlighting the need for antidotes use with DOACs.
Literatur
1.
Zurück zum Zitat Hart RG, Pearce LA, Aguilar MI (2007) Meta-analysis: antithrombotic therapy to prevent stroke in patients who have non valvular atrial fibrillation. Ann Intern Med 146(12):857–867CrossRefPubMed Hart RG, Pearce LA, Aguilar MI (2007) Meta-analysis: antithrombotic therapy to prevent stroke in patients who have non valvular atrial fibrillation. Ann Intern Med 146(12):857–867CrossRefPubMed
2.
Zurück zum Zitat Kearon C, Gent M, Hirsh J et al (1999) A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 340(12):901–907CrossRefPubMed Kearon C, Gent M, Hirsh J et al (1999) A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 340(12):901–907CrossRefPubMed
3.
Zurück zum Zitat Ruff CT, Giugliano RP, Braunwald E et al (2014) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383(9921):955–962CrossRefPubMed Ruff CT, Giugliano RP, Braunwald E et al (2014) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383(9921):955–962CrossRefPubMed
4.
Zurück zum Zitat Van Es N, Coppens M, Schulman S, Middeldorp S, Büller HR (2014) Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 124(12):1968–1975CrossRefPubMed Van Es N, Coppens M, Schulman S, Middeldorp S, Büller HR (2014) Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 124(12):1968–1975CrossRefPubMed
5.
Zurück zum Zitat Kirchhof P, Benussi S, Kotecha D et al (2016) 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37(38):2893–2962CrossRefPubMed Kirchhof P, Benussi S, Kotecha D et al (2016) 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37(38):2893–2962CrossRefPubMed
6.
Zurück zum Zitat Kearon C, Akl EA, Ornelas J et al (2016) Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 149(2):315–352CrossRefPubMed Kearon C, Akl EA, Ornelas J et al (2016) Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 149(2):315–352CrossRefPubMed
7.
Zurück zum Zitat Heidbuchel H, Verhamme P, Alings M et al (2015) Updated european heart rhythm association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 17(10):1467–1507CrossRefPubMed Heidbuchel H, Verhamme P, Alings M et al (2015) Updated european heart rhythm association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 17(10):1467–1507CrossRefPubMed
8.
Zurück zum Zitat Levy JH, Ageno W, Chan NC et al (2016) When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost 14:623–627CrossRefPubMed Levy JH, Ageno W, Chan NC et al (2016) When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost 14:623–627CrossRefPubMed
9.
Zurück zum Zitat Chai-Adisaksopha C, Crowther M, Isayama T, Lim W (2014) The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood 124(15):2450–2458CrossRefPubMed Chai-Adisaksopha C, Crowther M, Isayama T, Lim W (2014) The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood 124(15):2450–2458CrossRefPubMed
10.
Zurück zum Zitat Majeed A, Hwang HG, Connolly SJ et al (2013) Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation 128(21):2325–2332CrossRefPubMed Majeed A, Hwang HG, Connolly SJ et al (2013) Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation 128(21):2325–2332CrossRefPubMed
11.
Zurück zum Zitat Piccini JP, Garg J, Patel MR et al (2014) ROCKET AF investigators. Management of major bleeding events in patients treated with rivaroxaban vs warfarin: results from the ROCKET AF trial. Eur Heart J 35(28):1873–1880CrossRefPubMed Piccini JP, Garg J, Patel MR et al (2014) ROCKET AF investigators. Management of major bleeding events in patients treated with rivaroxaban vs warfarin: results from the ROCKET AF trial. Eur Heart J 35(28):1873–1880CrossRefPubMed
12.
Zurück zum Zitat Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) RE-LY steering committee and investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361(12):1139–1151CrossRefPubMed Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) RE-LY steering committee and investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361(12):1139–1151CrossRefPubMed
13.
Zurück zum Zitat Patel MR, Mahaffey KW, Garg J et al (2011) ROCKET AF investigators. Rivaroxaban versus warfarin in non valvular atrial fibrillation. N Engl J Med 365(10):883–891CrossRefPubMed Patel MR, Mahaffey KW, Garg J et al (2011) ROCKET AF investigators. Rivaroxaban versus warfarin in non valvular atrial fibrillation. N Engl J Med 365(10):883–891CrossRefPubMed
14.
Zurück zum Zitat Granger CB, Alexander JH, McMurray JJ et al (2011) ARISTOTLE committees and investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365(11):981–992CrossRefPubMed Granger CB, Alexander JH, McMurray JJ et al (2011) ARISTOTLE committees and investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365(11):981–992CrossRefPubMed
15.
Zurück zum Zitat Giugliano RP, Ruff CT, Braunwald E et al (2013) ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369(22):2093–2104CrossRefPubMed Giugliano RP, Ruff CT, Braunwald E et al (2013) ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369(22):2093–2104CrossRefPubMed
16.
Zurück zum Zitat Agnelli G, Buller HR, Cohen A et al (2013) AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369(9):799–808CrossRefPubMed Agnelli G, Buller HR, Cohen A et al (2013) AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369(9):799–808CrossRefPubMed
17.
Zurück zum Zitat Büller HR, Décousus H, Grosso MA et al (2013) Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 369(15):1406–1415CrossRefPubMed Büller HR, Décousus H, Grosso MA et al (2013) Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 369(15):1406–1415CrossRefPubMed
18.
Zurück zum Zitat Prins MH, Lensing AW, Bauersachs R et al (2013) Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J 11(1):21CrossRefPubMedPubMedCentral Prins MH, Lensing AW, Bauersachs R et al (2013) Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J 11(1):21CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Schulman S, Kakkar AK, Goldhaber SZ et al (2014) RE-COVER II trial investigators. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 129(7):764–772CrossRefPubMed Schulman S, Kakkar AK, Goldhaber SZ et al (2014) RE-COVER II trial investigators. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 129(7):764–772CrossRefPubMed
20.
Zurück zum Zitat Becattini C, Franco L, Beyer-Westendorf J et al (2016) Major bleeding with vitamin K antagonists or direct oral anticoagulants in real-life. Int J Cardiol 227:261–266CrossRefPubMed Becattini C, Franco L, Beyer-Westendorf J et al (2016) Major bleeding with vitamin K antagonists or direct oral anticoagulants in real-life. Int J Cardiol 227:261–266CrossRefPubMed
21.
Zurück zum Zitat Larsen TB, Rasmussen LH, Skjøth F et al (2013) Efficacy and safety of dabigatran etexilate and warfarin in “real-world” patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol 61(22):2264–2273CrossRefPubMed Larsen TB, Rasmussen LH, Skjøth F et al (2013) Efficacy and safety of dabigatran etexilate and warfarin in “real-world” patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol 61(22):2264–2273CrossRefPubMed
22.
Zurück zum Zitat Ageno W, Mantovani LG, Haas S et al (2016) Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study. Lancet Haematol 3(1):e12–e21CrossRefPubMed Ageno W, Mantovani LG, Haas S et al (2016) Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study. Lancet Haematol 3(1):e12–e21CrossRefPubMed
23.
Zurück zum Zitat Graham DJ, Reichman ME, Wernecke M et al (2015) Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for non valvular atrial fibrillation. Circulation 131(2):157–164CrossRefPubMed Graham DJ, Reichman ME, Wernecke M et al (2015) Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for non valvular atrial fibrillation. Circulation 131(2):157–164CrossRefPubMed
24.
Zurück zum Zitat Caldeira D, Rodrigues FB, Barra M et al (2015) Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis. Heart 101(15):1204–1211CrossRefPubMed Caldeira D, Rodrigues FB, Barra M et al (2015) Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis. Heart 101(15):1204–1211CrossRefPubMed
25.
Zurück zum Zitat Beyer-Westendorf J, Förster K, Pannach S et al (2014) Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood 124(6):955–962CrossRefPubMedPubMedCentral Beyer-Westendorf J, Förster K, Pannach S et al (2014) Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood 124(6):955–962CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Douketis JD, Spyropoulos AC, Spencer FA et al (2012) American College of Chest Physicians. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e326S–e350S Douketis JD, Spyropoulos AC, Spencer FA et al (2012) American College of Chest Physicians. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e326S–e350S
27.
Zurück zum Zitat Douketis JD, Healey JS, Brueckmann M et al. (2017) Urgent surgery or procedures in patients taking dabigatran or warfarin: analysis of perioperative outcomes from the RE-LY trial. Thromb Res 139:77–81CrossRef Douketis JD, Healey JS, Brueckmann M et al. (2017) Urgent surgery or procedures in patients taking dabigatran or warfarin: analysis of perioperative outcomes from the RE-LY trial. Thromb Res 139:77–81CrossRef
29.
Zurück zum Zitat Chai-Adisaksopha C, Hillis C, Siegal DM et al (2016) Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal. A systematic review and meta-analysis. Thromb Haemost 116(5):879–890CrossRefPubMed Chai-Adisaksopha C, Hillis C, Siegal DM et al (2016) Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal. A systematic review and meta-analysis. Thromb Haemost 116(5):879–890CrossRefPubMed
30.
Zurück zum Zitat Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M (2011) Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 124(14):1573–1579CrossRefPubMed Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M (2011) Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 124(14):1573–1579CrossRefPubMed
31.
Zurück zum Zitat Cheung YW, Barco S, Hutten BA, Meijers JC, Middeldorp S, Coppens M (2015) In vivo increase in thrombin generation by four-factor prothrombin complex concentrate in apixaban-treated healthy volunteers. J Thromb Haemost 13(10):1799–1805CrossRefPubMed Cheung YW, Barco S, Hutten BA, Meijers JC, Middeldorp S, Coppens M (2015) In vivo increase in thrombin generation by four-factor prothrombin complex concentrate in apixaban-treated healthy volunteers. J Thromb Haemost 13(10):1799–1805CrossRefPubMed
32.
Zurück zum Zitat Brown KS, Wickremasingha P, Parasrampuria DA et al (2015) The impact of a three-factor prothrombin complex concentrate on the anticoagulatory effects of the factor Xa inhibitor edoxaban. Thromb Res 136(4):825–831CrossRefPubMed Brown KS, Wickremasingha P, Parasrampuria DA et al (2015) The impact of a three-factor prothrombin complex concentrate on the anticoagulatory effects of the factor Xa inhibitor edoxaban. Thromb Res 136(4):825–831CrossRefPubMed
33.
Zurück zum Zitat Barco S, Whitney Cheung Y, Coppens M, Hutten BA, Meijers JC, Middeldorp S (2016) In vivo reversal of the anticoagulant effect of rivaroxaban with four-factor prothrombin complex concentrate. Br J Haematol 172(2):255–261CrossRefPubMed Barco S, Whitney Cheung Y, Coppens M, Hutten BA, Meijers JC, Middeldorp S (2016) In vivo reversal of the anticoagulant effect of rivaroxaban with four-factor prothrombin complex concentrate. Br J Haematol 172(2):255–261CrossRefPubMed
34.
Zurück zum Zitat Elg M, Carlsson S, Gustafsson D (2001) Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor. Thromb Res 101(3):145–157CrossRefPubMed Elg M, Carlsson S, Gustafsson D (2001) Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor. Thromb Res 101(3):145–157CrossRefPubMed
35.
Zurück zum Zitat Marlu R, Hodaj E, Paris A, Albaladejo P, Cracowski JL, Pernod G (2012) Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 108(2):217–224CrossRefPubMed Marlu R, Hodaj E, Paris A, Albaladejo P, Cracowski JL, Pernod G (2012) Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 108(2):217–224CrossRefPubMed
36.
Zurück zum Zitat Mao G, King L, Young S, Kaplan R (2016) Factor eight inhibitor bypassing agent (FEIBA) for reversal of target-specific oral anticoagulants in life-threatening intracranial bleeding. J Emerg Med. doi:10.1016/j.jemermed.2016.11.011 Mao G, King L, Young S, Kaplan R (2016) Factor eight inhibitor bypassing agent (FEIBA) for reversal of target-specific oral anticoagulants in life-threatening intracranial bleeding. J Emerg Med. doi:10.​1016/​j.​jemermed.​2016.​11.​011
37.
Zurück zum Zitat Dibu JR, Weimer JM, Ahrens C, Manno E, Frontera JA (2016) The Role of FEIBA in reversing novel oral anticoagulants in intracerebral hemorrhage. Neurocrit Care 24(3):413–419CrossRefPubMed Dibu JR, Weimer JM, Ahrens C, Manno E, Frontera JA (2016) The Role of FEIBA in reversing novel oral anticoagulants in intracerebral hemorrhage. Neurocrit Care 24(3):413–419CrossRefPubMed
38.
Zurück zum Zitat Schiele F, van Ryn J, Canada K et al (2013) A specific antidote for dabigatran: functional and structural characterization. Blood 121(18):3554–3562CrossRefPubMed Schiele F, van Ryn J, Canada K et al (2013) A specific antidote for dabigatran: functional and structural characterization. Blood 121(18):3554–3562CrossRefPubMed
39.
Zurück zum Zitat Glund S, Moschetti V, Norris S et al (2015) A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thromb Haemost 113(5):943–945CrossRefPubMed Glund S, Moschetti V, Norris S et al (2015) A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thromb Haemost 113(5):943–945CrossRefPubMed
40.
Zurück zum Zitat Glund S, Stangier J, Schmohl M et al (2015) Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet 386(9994):680–690CrossRefPubMed Glund S, Stangier J, Schmohl M et al (2015) Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet 386(9994):680–690CrossRefPubMed
41.
42.
Zurück zum Zitat Dentali F, Marchesi C, Giorgi Pierfranceschi M et al (2011) Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis. Thromb Haemost 106(3):429–438CrossRefPubMed Dentali F, Marchesi C, Giorgi Pierfranceschi M et al (2011) Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis. Thromb Haemost 106(3):429–438CrossRefPubMed
43.
Zurück zum Zitat Goldstein JN, Refaai MA, Milling TJ Jr et al (2015) Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. Lancet 385:2077–2087CrossRefPubMed Goldstein JN, Refaai MA, Milling TJ Jr et al (2015) Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. Lancet 385:2077–2087CrossRefPubMed
44.
Zurück zum Zitat Lu G, DeGuzman FR, Hollenbach SJ et al (2013) A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 19(4):446–451CrossRefPubMed Lu G, DeGuzman FR, Hollenbach SJ et al (2013) A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 19(4):446–451CrossRefPubMed
45.
Zurück zum Zitat Siegal DM, Curnutte JT, Connolly SJ et al (2015) Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 373(25):2413–2424CrossRefPubMed Siegal DM, Curnutte JT, Connolly SJ et al (2015) Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 373(25):2413–2424CrossRefPubMed
46.
Zurück zum Zitat Connolly SJ, Milling TJ Jr, Eikelboom JW et al (2016) ANNEXA-4 investigators. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med 375(12):1131–1141CrossRefPubMedPubMedCentral Connolly SJ, Milling TJ Jr, Eikelboom JW et al (2016) ANNEXA-4 investigators. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med 375(12):1131–1141CrossRefPubMedPubMedCentral
47.
Zurück zum Zitat Sullivan DW Jr, Gad SC, Laulicht B, Bakhru S, Steiner S (2015) Non clinical safety assessment of PER977: a small molecule reversal agent for new oral anticoagulants and heparins. Int J Toxicol 34(4):308–317CrossRefPubMed Sullivan DW Jr, Gad SC, Laulicht B, Bakhru S, Steiner S (2015) Non clinical safety assessment of PER977: a small molecule reversal agent for new oral anticoagulants and heparins. Int J Toxicol 34(4):308–317CrossRefPubMed
48.
Zurück zum Zitat Ansell JE, Bakhru SH, Laulicht BE et al (2014) Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med 371(22):2141–2142CrossRefPubMed Ansell JE, Bakhru SH, Laulicht BE et al (2014) Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med 371(22):2141–2142CrossRefPubMed
49.
Zurück zum Zitat Ansell JE, Laulicht BE, Bakhru SH, Hoffman M, Steiner SS, Costin JC (2016) Ciraparantag safely and completely reverses the anticoagulant effects of low molecular weight heparin. Thromb Res 146:113–118CrossRefPubMed Ansell JE, Laulicht BE, Bakhru SH, Hoffman M, Steiner SS, Costin JC (2016) Ciraparantag safely and completely reverses the anticoagulant effects of low molecular weight heparin. Thromb Res 146:113–118CrossRefPubMed
50.
Zurück zum Zitat Ansell JE, Bakhru SH, Laulicht BE et al (2017) Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban. Thromb Haemost 26(2):238–245 117 Ansell JE, Bakhru SH, Laulicht BE et al (2017) Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban. Thromb Haemost 26(2):238–245 117
51.
Zurück zum Zitat van Ryn J, Stangier J, Haertter S et al (2010) Dabigatran etexilate–a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 103(6):1116–1127CrossRefPubMed van Ryn J, Stangier J, Haertter S et al (2010) Dabigatran etexilate–a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 103(6):1116–1127CrossRefPubMed
52.
Zurück zum Zitat Ageno W, Büller HR, Falanga A et al (2016) Managing reversal of direct oral anticoagulants in emergency situations. Anticoagulation Education Task Force White Paper. Thromb Haemost 116(6):1003–1010CrossRefPubMed Ageno W, Büller HR, Falanga A et al (2016) Managing reversal of direct oral anticoagulants in emergency situations. Anticoagulation Education Task Force White Paper. Thromb Haemost 116(6):1003–1010CrossRefPubMed
53.
Zurück zum Zitat Stangier J, Rathgen K, Stähle H, Gansser D (2007) Roth W:The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 64:292–303CrossRefPubMedPubMedCentral Stangier J, Rathgen K, Stähle H, Gansser D (2007) Roth W:The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 64:292–303CrossRefPubMedPubMedCentral
Metadaten
Titel
Reversal of dabigatran-associated bleeding using idarucizumab: review of the current evidence
verfasst von
Michela Giustozzi
Melina Verso
Giancarlo Agnelli
Cecilia Becattini
Publikationsdatum
14.09.2017
Verlag
Springer US
Erschienen in
Journal of Thrombosis and Thrombolysis / Ausgabe 4/2017
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-017-1555-4

Weitere Artikel der Ausgabe 4/2017

Journal of Thrombosis and Thrombolysis 4/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.